<DOC>
	<DOCNO>NCT01693640</DOCNO>
	<brief_summary>Hypothesis : Abatacept injection decrease number oral ulcer see Behcet 's patient</brief_summary>
	<brief_title>A Pilot Study Safety Efficacy Abatacept Injections Treatment Behcet 's Syndrome</brief_title>
	<detailed_description>This open label study , 20 Behcet 's patient resistant oral ulcer 10 resistant genital ulcer enrol ( screen 40 ) . After enrollment patient follow month document number oral genital ulcer current regimen . Then patient receive abatacept 6 month ( evaluated week 0 , 2 , 4 , 8 , 12 , 16 24 ) . Then treatment stop observe next 2 month , total 9 month trial .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Inclusion Criteria 1 . Before study procedure perform , subject detail study describe , give write informed consent document read . Then , subject consent participate study , indicate consent sign date informed consent document presence study personnel . 2 . Female patient diagnosis Behcet 's syndrome 3 . Women , great 18 year age 4 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 10 week last dose study drug minimize risk pregnancy . 5 . Patients must oral ulcer genital ulcer resistant colchicine topical measure least month . 1 . WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 10 week last dose study drug . 2 . Women pregnant breastfeeding . 3 . Women positive pregnancy test enrollment administration abatacept . Target Disease Exceptions [ Include applicable ] Any patient systemic manifestation Behcet 's syndrome ( Patients eye , CNS , vascular involvement , gastrointestinal disease ) Patients already immunosuppressive medication ( azathioprine , TNF inhibitor , biologic agent , methotrexate , mycophenolate mofetil , cyclosporine , cyclophosphamide ) 4 . Subjects impair , incapacitate , incapable completing studyrelated assessment . 5 . Subjects current symptom severe , progressive , uncontrolled renal , hepatic , hematologic , gastrointestinal , pulmonary , cardiac , neurologic , cerebral disease , whether related Behcet 's syndrome , opinion investigator , might place subject unacceptable risk participation study . 6 . Female subject breast cancer screen suspicious malignancy possibility malignancy reasonably exclude additional clinical , laboratory , diagnostic evaluation . 7 . Subjects history cancer last 5 year , nonmelanoma skin cell cancer cure local resection carcinoma situ . 8 . Subjects currently abuse drug alcohol . 9 . Subjects evidence ( assessed investigator ) active latent bacterial viral infection time potential enrollment , include subject evidence human immunodeficiency virus ( HIV ) detect screen . 10 . Subjects herpes zoster cytomegalovirus ( CMV ) resolve less 2 month inform consent document sign . 11 . Subjects receive live vaccine within 3 month anticipate first dose study medication . 12 . Subjects serious bacterial infection within last 3 month , unless treat resolved antibiotic , chronic bacterial infection ( eg , chronic pyelonephritis , osteomyelitis , bronchiectasis ) . 13 . Subjects risk tuberculosis ( TB ) . 14 . Subjects must positive hepatitis B surface antigen . 15 . Subjects positive hepatitis C antibody presence hepatitis C virus also show polymerase chain reaction recombinant immunoblot assay . 16 . Subjects follow laboratory value 17 . Hemoglobin &lt; 8.5 g/dL 18 . WBC &lt; 3000/mm3 ( &lt; 3 x 109/L ) 19 . Platelets &lt; 100,000/mm3 ( &lt; 3 x 109/L ) 20 . Serum creatinine &gt; 2 time ULN 21 . Serum ALT AST &gt; 2 time ULN 22 . Any laboratory test result , opinion investigator , might place subject unacceptable risk participation study . 23 . Subjects time receive treatment investigational drug within 28 day ( less 5 terminal halflives elimination ) Day 1 dose . 24 . Any concomitant biologic DMARD .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Behcet 's</keyword>
</DOC>